NEOGENOMICS INC

NeoGenomics insider sale: Tetrault Lynn A. sells 5,307 shares at $11.10 amid debt‑heavy capital structure—investors weigh liquidity vs. future growth potential.

NeoGenomics insider buying signals growth‑to‑profit shift: 5,893 shares at $10.12, 30%+ insider stake rise, 12‑month gain 12.67%, yet negative P/E warns of dilution risk.

Stone Warren’s latest NeoGenomics purchase signals confidence in the firm’s defense partnership and silicon‑anode battery tech, hinting at future upside for investors.

NeoGenomics insider moves: COO Greg Aunan’s $9.54 option buy shows confidence amid a 23 % dip, hinting at a potential turnaround with new product launches.

NeoGenomics CFO Abhishek Jain’s March 2026 option grant signals confidence in the new RaDaR ST platform—could boost shareholder value if the company turns profitable.